Home
FDA Approved Alnylam Pharmaceuticals sNDA for AMVUTTRA® – A Treatment for Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis in Adults to Reduce Cardiovascular Mortality, Cardiovascular Hospitalizations and Urgent Heart Failure Visits

FDA Approved Alnylam Pharmaceuticals sNDA for AMVUTTRA® – A Treatment for Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis in Adults to Reduce Cardiovascular Mortality, Cardiovascular Hospitalizations and Urgent Heart Failure Visits

Today’s Highlights March 21, 2025

Alnylam Pharmaceuticals in the NEWS

March 20, 2025, Alnylam Pharmaceuticals (ALNY) - the leading RNAi therapeutics company, today announced that the U.S. FDA has approved the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
March 21, 2025

Other Articles